(NASDAQ: BTAI) Bioxcel Therapeutics's forecast annual revenue growth rate of 397.07% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.04%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.47%.
Bioxcel Therapeutics's revenue in 2026 is $742,000.On average, 7 Wall Street analysts forecast BTAI's revenue for 2026 to be $30,654,345, with the lowest BTAI revenue forecast at $23,623,130, and the highest BTAI revenue forecast at $36,502,212. On average, 6 Wall Street analysts forecast BTAI's revenue for 2027 to be $890,578,836, with the lowest BTAI revenue forecast at $637,505,182, and the highest BTAI revenue forecast at $1,150,477,088.
In 2028, BTAI is forecast to generate $3,193,160,898 in revenue, with the lowest revenue forecast at $3,067,938,902 and the highest revenue forecast at $3,287,077,395.